Alnylam Pharmaceuticals presents new data related to its overall delivery research efforts
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it presented new data related to its overall delivery research efforts including the rational design of Mimetic Lipoprotein Particles, or MLPs, a novel technology for the systemic delivery of small interfering RNAs, or siRNAs, the molecules that mediate RNAi.
Alnylam Pharmaceuticals, Inc. has announced that it has consolidated the key intellectual property for RNA activation, creating a dominant IP position in this new area of biology.